ArticleHeart (British Cardiac Society)2002
Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?
Article in Heart (British Cardiac Society), 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort.The British journal of general practice : the journal of the Royal College of General Practitioners · 2012Trial
- Effects of an enhanced secondary prevention program for patients with heart disease: a prospective randomized trial.The Canadian journal of cardiology · 2007Trial
- Multiple Socioeconomic Circumstances and Initiation of Cardiovascular Medication among Ageing Employees.International journal of environmental research and public health · 2021Article
- Barriers in utilizing lipid-lowering agents in non-institutionalized population in the U.S.: Application of a theoretical framework.PloS one · 2021Article
- Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink.Gut · 2019Article
- Statin-prescribing trends for primary and secondary prevention of cardiovascular disease.Canadian family physician Medecin de famille canadien · 2017Article
- Neighborhood socioeconomic characteristics and statin medication in patients with myocardial infarction: a Swedish nationwide follow-up study.BMC cardiovascular disorders · 2016Article
- Article
- Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study.BMC public health · 2012Article
- Statins and their interactions with other lipid-modifying medications: safety issues in the elderly.Therapeutic advances in drug safety · 2012Review
- Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective cohort study.Atherosclerosis · 2011Article
- Neighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: atherosclerosis risk in communities (ARIC) community surveillance.BMC public health · 2010Article
- Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations.Drugs & aging · 2009Review
- Cardiorespiratory risk factors as predictors of 40-year mortality in women and men.Heart (British Cardiac Society) · 2009Article
- Importance of socioeconomic status as a predictor of cardiovascular outcome and costs of care in women with suspected myocardial ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE).Journal of women's health (2002) · 2008Article
- Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients.International journal for equity in health · 2008Article
- Gender differences in the clinical management of patients with angina pectoris: a cross-sectional survey in primary care.BMC health services research · 2007Article
- Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study.Journal of public health (Oxford, England) · 2007Article
- How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England.International journal for equity in health · 2007Article
- Which doctors are influenced by a patient's age? A multi-method study of angina treatment in general practice, cardiology and gerontology.Quality & safety in health care · 2007Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate possible inequities in the use of statins for people with coronary heart disease according to a wide range of social and clinical factors. DESIGN AND
settingCross sectional analysis of data from the Health Survey for England 1998, a population based survey. SUBJECTS: 760 adults with coronary heart disease.
resultsOnly 19.9% of subjects with coronary heart disease were receiving lipid lowering drugs (151 of 760; 95% confidence interval (CI) 17.0% to 22.7%). The likelihood of receiving statins was greatly reduced for older age groups: compared with those aged less than 65 years, the odds of receiving statin treatment were 0.53 (95% CI 0.35 to 0.80) for subjects aged 65-74 years, and 0.11 (95% CI 0.06 to 0.21) for subjects aged 75 years and over. Statins were given less often to current cigarette smokers than to non-smokers (odds ratio 0.55, 95% CI 0.32 to 0.96), and to subjects with angina compared with those with a previous myocardial infarct (odds ratio 0.63, 95% CI 0.43 to 0.93). Lower levels of statin use were also seen with increasing time since diagnosis (p = 0.12). No clear associations were observed with social measures.
conclusionsImportant inequalities were found in the use of statins among people with coronary heart disease, which could not be justified by evidence from the large statin trials. Proactive policies are required to ensure that the vast majority of (if not all) patients with coronary heart disease are receiving statins, regardless of age, sex, social class, smoking status, type of coronary heart disease, or time since diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.